This activity is for healthcare professionals in the USA.

This activity is provided by an independent medical education grant from Sanofi.

The activity is jointly provided by USF Health and touchIME.

Faculty & Disclosures

Listen on the go

View and download resources from this activity to support your learning and share with colleagues.

Download Slides
CORRECT!
Next question
Faculty & Disclosures
Prof. Cindy Neunert

Columbia University Irving Medical Center, New York, NY, USA

Prof. Cindy Neunert is an associate professor of paediatrics at Columbia University in New York. read more

She received fellowship training in paediatric haematology–oncology at the University of Texas Southwestern Medical School at Dallas in Texas, where she also obtained her master’s degree in clinical research.

Her research interests involve assessing patient-related outcomes in disorders of haemostasis and thrombosis. She was chair of the 2019 American Society of Hematology guidelines on the diagnosis and management of immune thrombocytopenia (ITP). She works closely with the Intercontinental Cooperative ITP Study Group and is the former chair of the Pediatric ITP Consortium of North America.

Prof. Cindy Neunert discloses: Advisory board or panel fees from Janssen; Argenx, Sanofi and Sobi (relationships terminated). Other financial or material support from Genzyme and Sanofi (relationships terminated).
Prof. David Kuter

Massachusetts General Hospital, Boston, MA, USA

Prof. David Kuter is chief of haematology at Massachusetts General Hospital (MGH) and professor of medicine at Harvard Medical School in Boston. read more

Prof. Kuter divides his time between medical education of fellows and medical students, clinical care of patients with a wide range of haematological disorders, basic science investigation into thrombopoietin and megakaryocyte biology, and clinical research related to thrombopoietic agents and haemolytic anaemia. His basic science group was one of the laboratories that discovered thrombopoietin and his clinical research group carried out various seminal studies using thrombopoietic agents in transfusion medicine, chemotherapy-induced thrombocytopenia and immune thrombocytopenia.

A member of the American Society of Hematology (ASH), Prof. Kuter is the recipient of a number of awards, including the Irving M. London Teaching Award at Harvard Medical School; the Alfred Kranes Teaching Award at MGH; the 2008 and 2010 Douglas Family Foundation Prize, recognizing excellence in haematology–oncology research at the MGH Cancer Center; the Jane Green Memorial Prize, recognizing excellence in haematology–oncology teaching at the MGH Cancer Center; the 2013 Ernest Beutler Award from ASH; the Thomas R. Spitzer Outstanding Clinician Award at the MGH Cancer Center; and the 2023 MacFarlane Biggs Plenary Lectureship of the British Society for Haematology/British Society for Haemostasis and Thrombosis.

Prof. Kuter has given over 700 invited lectures in over 50 countries and served as a visiting professor in Beijing, Sydney, Tokyo, London, Durham, Little Rock, Tianjin, Melbourne, and New Haven. Prof. Kuter has authored or co-authored over 350 articles published in international, peer-reviewed journals, including the New England Journal of Medicine, The Lancet and Blood.

Prof. David Kuter discloses: Consultant for Alexion, Alpine, Amgen, Apellis, Argenx, BioCryst, Bristol Myers Squibb, Caremark, Cellphire, Cellularity, Chugai, Hengrui, Hutchmed, Immunovant, Inmagenebio, Ligand, Merck Sharp Dohme, Novartis, Pfizer, Principia, Regeneron, Rigel, Sanofi, Seismic, Sobi, Takeda, UCB and Verve. Grants/research support from Biocrystal, Hutchmed, Novartis, Principia, Rigel and Sanofi.
Dr María Eva Mingot Castellano

Hospital Universitario Virgen del Rocío, Seville, Spain

Dr María Eva Mingot Castellano is the head of transfusion and tissue establishment area in the Hematology Department, including apheresis and cryopreservation, at the Virgen del Rocío University Hospital, in Seville, Spain. read more

From 2005 to 2019 she was responsible for haemostasis and thrombosis in adults in the Hematology Department of the Regional University Hospital of Malaga. She has been an associate professor at the University of Seville since 2023 and at the University of Malaga from 2011 to 2019.

Dr Mingot Castellano is a member of the board of the Spanish Society of Thrombosis and Haemostasis and the Transfusion Accreditation Committee; vice president of the Spanish Apheresis Group; treasurer reference of the Spanish Immune Thrombocytopenia (ITP) Working Group; and coordinator of the Spanish and Portuguese thrombotic thrombocytopenic purpura (TTP) Registry, the Spanish registry of acquired haemophilia, the national ITP and TTP guidelines.

As of January 2024, Dr Mingot Castellano had 185 documents in Web of Science. Her main areas of interest are immune cytopenias (immune haemolytic anaemia, ITP, TTP, congenital immune cytopenia, acquired haemophilia), critical bleeding, clinical transfusion, haemovigilance and patient blood management.

Dr María Eva Mingot Castellano discloses: Advisory board or panel fees from Amgen, Grifols, Novartis, Novo Nordisk, Sanofi, Sobi and Takeda. Consultant for Amgen, Grifols, Novartis, Novo Nordisk, Sanofi, Sobi and Takeda. Grants/research support from Amgen, Grifols, Novartis, Novo Nordisk, Sanofi, Sobi and Takeda. Speaker’s bureau fees from Amgen, Grifols, Novartis, Novo Nordisk, Sanofi, Sobi and Takeda.
Back to Faculty
touchONCOLOGY touchONCOLOGY
Start activity
 
Videos Take CE/CME Test
Haematology, Rare Diseases CE/CME accredited

touchSYMPOSIUM
An enduring activity from a live meeting, experts discuss pertinent data which could improve patient care and outcomes. Close

Collaboration in chronic ITP: Improving quality of life and patient outcomes

Faculty Featured
Learning Objectives

After watching this activity, participants should be better able to:

  • Explain the natural history of chronic ITP and its impact on patients
  • Discuss current and future treatment strategies to improve the HRQoL of patients with chronic ITP
  • Practice shared decision-making and collaboration to optimize outcomes for patients with chronic ITP
Overview

In this symposium preceding the 66th ASH Annual Meeting and Exposition, hear a patient’s view on the impact of living with immune thrombocytopenia (ITP) and its effect on health-related quality of life. Following this, the expert faculty – Prof. Cindy Neunert (Chair), Prof. David Kuter and Dr María Eva Mingot Castellano – provide practical insights on current and emerging treatments for chronic ITP and how these may be utilized to improve outcomes for patients, including case-based presentations to review management strategies for different patient profiles. Finally, a panel discussion with all three faculty focuses on shared decision-making and collaboration in the clinic, to give patients with chronic ITP the best possible outcomes.

This activity is jointly provided by USF Health and touchIME. read more

Target Audience

Haematologists, including haemato-oncologists, nurses and nurse practitioners involved in the management of ITP.

Disclosures

USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.

Faculty

Prof. Cindy Neunert discloses: Advisory board or panel fees from Janssen; Argenx, Sanofi and Sobi (relationships terminated). Other financial or material support from Genzyme and Sanofi (relationships terminated).

Prof. David Kuter discloses: Consultant for Alexion, Alpine, Amgen, Apellis, Argenx, BioCryst, Bristol Myers Squibb, Caremark, Cellphire, Cellularity, Chugai, Hengrui, Hutchmed, Immunovant, Inmagenebio, Ligand, Merck Sharp Dohme, Novartis, Pfizer, Principia, Regeneron, Rigel, Sanofi, Seismic, Sobi, Takeda, UCB and Verve. Grants/research support from Biocrystal, Hutchmed, Novartis, Principia, Rigel and Sanofi.

Dr María Eva Mingot Castellano discloses: Advisory board or panel fees from Amgen, Grifols, Novartis, Novo Nordisk, Sanofi, Sobi and Takeda. Consultant for Amgen, Grifols, Novartis, Novo Nordisk, Sanofi, Sobi and Takeda. Grants/research support from Amgen, Grifols, Novartis, Novo Nordisk, Sanofi, Sobi and Takeda. Speaker’s bureau fees from Amgen, Grifols, Novartis, Novo Nordisk, Sanofi, Sobi and Takeda.

Content reviewer

Danielle Walker, DNP, APRN, AGNP-C, has no financial interests/relationships or affiliations in relation to this activity.

Touch Medical Contributors

Hannah Fisher and Katrina Lester have no financial interests/relationships or affiliations in relation to this activity.

USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.

Requirements for Successful Completion

In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.

If you have questions regarding credit please contact cpdsupport@usf.edu

Accreditations

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

USF Health designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

Advanced Practice Providers

Physician Assistants may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.

The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.

Nurses

USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

A maximum of 1.5 contact hours may be earned by learners who successfully complete this continuing professional development activity. USF Health, the accredited provider, acknowledges touchIME as the joint provider in the planning and execution of this CNE activity.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hour.

Date of original release: 10 December 2024. Date credits expire: 10 December 2027.

If you have any questions regarding credit, please contact cpdsupport@usf.edu

This activity is CE/CME accredited

To obtain the CE/CME credit(s) from this activity, please complete this post-activity test.

Claim Credit

You may also be interested in...

touchPANEL DISCUSSION

Maximizing the possibilities in the evolving treatment paradigm for R/R follicular lymphoma: From optimal sequencing to shared decision-making

This activity is CE/CME accredited
LAUNCH ACTIVITY

touchPANEL DISCUSSION

Keeping pace with the evolving treatment paradigm for relapsed/refractory multiple myeloma: Earlier use of novel agents

This activity is CE/CME accredited
LAUNCH ACTIVITY

CONFERENCE HUB

George Goshua, EHA 2020: Endotheliopathy is Essential in COVID-19 Associated Coagulopathy

GO TO HUB

CONFERENCE HUB

EHA 2019 – Day 1 Highlights!

GO TO HUB

JOURNALS

Foreword – US Oncological Disease, 2007;1(2):6

GO TO ARTICLE

JOURNALS

Education, Mentoring, and Collaborative Research—The Mission of the Hemophilia & Thrombosis Research Society

GO TO ARTICLE

Topics covered in this activity

Haematology / Rare Diseases
REGISTER NOW FOR FREE ACCESS TO
  • 1000+ topical and insightful peer-reviewed journal articles
  • 100+ hours of bite-sized congress highlights
  • 8 major therapy areas packed with the latest scientific advances
  • 150+ specialties offering learn-on-the-go medical education
  • + Concise email updates and newsletters so you never miss out
Register For Free Now
This Activity Is Funded By:

An independent medical education grant from Sanofi. This activity is jointly provided by USF Health and touchIME.

Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

This content is intended only for healthcare professionals in the USA.

Date of original release: 10 December 2024. Date credits expire: 10 December 2027.

Claim Credit
touchSYMPOSIUM
Collaboration in chronic ITP: Improving quality of life and patient outcomes
1.5 CE/CME credit
Question 1/2
Your patient has recently been diagnosed with immune thrombocytopenia. You want to assess how immune thrombocytopenia is affecting their quality of life. Which of the following patient reported outcome measures would you use?

Fatigue is frequently reported as the most debilitating symptom of ITP.1 The FACIT-F PRO measure can be used to assess the levels of fatigue in patients with ITP.2 The Edmonton symptom assessment system and memorial symptom assessment scale are used to measure symptoms commonly associated with cancer.3 Pain is not a symptom commonly associated with ITP.1

Abbreviations

FACIT-F, functional assessment of chronic illness therapy – fatigue; ITP, immune thrombocytopenia; PRO, patient-reported outcome.

References

  1. Kruse C, et al. Ann Blood. 2021;6:9.
  2. Maitland H, et al. Hematology. 2024;29:2375177.
  3. EHA. Guidelines patient reported-outcomes in haematology. Available at: https://ehaweb.org/assets/Uploads/EHA-Guideline-libro.pdf (accessed 05 December 2024).
Question 2/2
As a result of your participation in this session, will you make a change in your practice?
Back to Activity

You may also be interested in...

touchSYMPOSIUM

Collaboration in chronic ITP: Improving quality of life and patient outcomes

This activity is CE/CME accredited
LAUNCH ACTIVITY

touchIN CONVERSATION

Managing the practicalities of CAR T-cell therapies in patients with R/R MCL: Current considerations and future strategies

This activity is CE/CME accredited
LAUNCH ACTIVITY

CONFERENCE HUB

Antonis Kattamis, EHA 2019 – Transfusion-dependent Thalassemia and the DEEP-2 Trial

GO TO HUB

CONFERENCE HUB

Jo Howard, MD, EHA 2019 – Results from the HOPE trial

GO TO HUB

JOURNALS

D-dimer Testing and Venous Thromboembolism

GO TO ARTICLE

JOURNALS

Subnormal Vitamin B12 Concentrations and Anaemia in Older Persons

GO TO ARTICLE
This Activity Is Funded By:

An independent medical education grant from Sanofi. This activity is jointly provided by USF Health and touchIME.

Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

This content is intended only for healthcare professionals in the USA.

Date of original release: 10 December 2024. Date credits expire: 10 December 2027.

Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup